MLN 3897 manufacturers
- MLN-3897
-
- $4180.00
-
2026-07-27
- CAS:1010731-97-1
- Purity: 98.62%
- Supply Ability: 10g
|
| | MLN 3897 Basic information |
| Product Name: | MLN 3897 | | Synonyms: | MLN 3897;[1]Benzoxepino[3,4-b]pyridine-7-carboxylic acid, 5-[3-[(4R)-5-(4-chlorophenyl)-4-hydroxy-3,3-dimethyl-1-piperidinyl]propylidene]-5,11-dihydro-;AVE 9897;AVE9897;AVE-9897;CCR1 antagonist 10 | | CAS: | 1010731-97-1 | | MF: | C30H31ClN2O4 | | MW: | 519.03 | | EINECS: | | | Product Categories: | | | Mol File: | 1010731-97-1.mol |  |
| | MLN 3897 Chemical Properties |
| Boiling point | 716.2±60.0 °C(Predicted) | | density | 1.304±0.06 g/cm3(Predicted) | | pka | 4.16±0.20(Predicted) |
| | MLN 3897 Usage And Synthesis |
| Description | MLN-3897, also known as AVE-9897, is a C-C Motif Chemokine Receptor 1 (CCR1) antagonist potentially for the treatment of multiple sclerosis and rheumatoid arthritis. MLN3897 abrogates its effects by inhibiting Akt signaling. Moreover, MM cell-to-OC adhesion was abrogated by MLN3897, thereby inhibiting MM cell survival and proliferation. MLN3897 demonstrates significant impairment of OC formation (by 40%) and function (by 70%), associated with decreased precursor cell multinucleation and down-regulation of c-fos signaling. | | Uses | CCR1 antagonist 10 (example 1) is a potent and orally active CCR1 antagonist. CCR1 antagonist 10 inhibits 125I-MIP-1α binding to THP-1 cell membranes with an Ki value of 2.3 nM[1]. | | IC 50 | CCR1 | | References | [1] Kenneth G. Carson, et al. Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease. WO2004043965A1. |
| | MLN 3897 Preparation Products And Raw materials |
|